Subtitle
A comparison of the outcomes between surgical resection and proton beam therapy for single primary hepatocellular carcinoma.
Subtitle
A comparison of the outcomes between surgical resection and proton beam therapy for single primary hepatocellular carcinoma.
Proto therapy Time
October 2019
Executive summary
There were 314 and 31 patients with single primary nodular HCC ≤ 100 mm without vessel invasion who underwent surgical resection (SR) and PBT were analyzed. The study reported that the median survival time in the SR group was significantly better than in the PBT group (104.1 vs. 64.6 months, p = 0.008) with no difference on the relapse-free survival (RFS) between the two groups.
The study concluded that SR may therefore be favorable as an initial treatment for HCC compared to PBT.
Top cancer treatments
Related contents
Proton Therapy Publication
September 2024
Cost-utility analysis of proton beam therapy for locally advanced esophageal cancer in Japan.
Proton Therapy Publication
September 2024
Particle therapy in gastrointestinal cancer-a narrative review.
Proton Therapy Publication
September 2024
Clinical Outcomes of Proton Beam Therapy for Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Retrospective Study.
Proton Therapy Publication
June 2024
Effectiveness and Safety of Carbon Ion Radiotherapy in Solid Tumors: A Systematic Review and Meta-Analysis.
Proton Therapy Publication
June 2024
Optimizing GRID and Lattice Spatially Fractionated Radiation Therapy: Innovative Strategies for Radioresistant and Bulky Tumor Management.
Proton Therapy Publication
May 2024
PTCOG Gastrointestinal Subcommittee Lower Gastrointestinal Tract Malignancies Consensus Statement.
Proton Therapy Publication
May 2024
Comparing 90-Day Postoperative Mortality After Neoadjuvant Proton-Based Versus Photon-Based Chemoradiotherapy for Esophageal Cancer.
Proton Therapy Publication
May 2024
Proton Beam Radiotherapy as a Curative Alternative to Radiofrequency Ablation for Newly Diagnosed Hepatocellular Carcinoma.
Proton Therapy Publication
May 2024
Hypofractionated Radiotherapy-Related Lymphopenia Is Associated With Worse Survival in Unresectable Intrahepatic Cholangiocarcinoma.